529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study

BACKGROUND: In the TACKLE phase 3 outpatient treatment study, 600-mg AZD7442 (tixagevimab/cilgavimab) in adults with mild to moderate COVID-19 significantly reduced progression to severe disease or death over 29 days and was well-tolerated at primary analysis. Here, we report final safety findings f...

Descripción completa

Detalles Bibliográficos
Autores principales: Richard Hobbs, F D, Montgomery, Hugh, Padilla, Francisco, Campos, Jesus Abraham Simón, Arbetter, Douglas, Seegobin, Seth, Kiazand, Alexandre, Streicher, Katie, Martinez-Alier, Nuria, Cohen, Taylor, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677991/
http://dx.doi.org/10.1093/ofid/ofad500.598

Ejemplares similares

Ejemplares similares